-+ 0.00%
-+ 0.00%
-+ 0.00%

Gyre Therapeutics forecasts FY26 ETUARY revenue at $100.5 million-$111 million

PUBT·08/26/2026 13:05:24
Listen to the news
Gyre Therapeutics forecasts FY26 ETUARY revenue at $100.5 million-$111 million
  • Gyre Therapeutics outlined a strategy to fund targeted protein degrader and degrader antibody-conjugate programs using China commercial cash flows.
  • FY26 ETUARY total revenue guidance set at $100.5-$111 million from its market-leading pirfenidone brand in China for idiopathic pulmonary fibrosis.
  • Hydronidone (F351) NDA filing accepted by China’s NMPA in May 2026; potential launch in early 2027 for CHB-induced liver fibrosis.
  • Two degrader candidates targeted for IND submission in Q1 2027, with Phase 1 starts planned in 2027 in the U.S. or China.
  • Pan-TRK degrader CG00141G completed Phase 1 in healthy volunteers; Phase 2 planning for cancer-induced bone pain in the U.S. or China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.